129 related articles for article (PubMed ID: 37845834)
1. Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
Massoud R; Naim H; Klyuchnikov E; Janson D; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2024 Feb; 112(2):276-285. PubMed ID: 37845834
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
3. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
4. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.
Picleanu AM; Novelli S; Monter A; Garcia-Cadenas I; Caballero AC; Martino R; Esquirol A; Briones J; Sierra J
Ann Hematol; 2017 May; 96(5):787-796. PubMed ID: 28168350
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845
[TBL] [Abstract][Full Text] [Related]
8. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
12. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.
Mercadal S; Mussetti A; Lee CJ; Arevalo C; Odstrcil SM; Peña E; Sureda A; Couriel DR
Ann Hematol; 2024 May; 103(5):1717-1727. PubMed ID: 38429536
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
15. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
[TBL] [Abstract][Full Text] [Related]
16. Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
Fanelli F; Hohaus S; Cantonetti M; Cimino G; Pennese E; Battistini R; Galli E; Cerretti R; Proia A; Fatone F; Provenzano I; Abruzzese E; Finolezzi E; Pulsoni A; Rigacci L
Chemotherapy; 2023; 68(3):131-137. PubMed ID: 36549287
[TBL] [Abstract][Full Text] [Related]
17. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D
Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
Clavert A; Le Gouill S; Brissot E; Dubruille V; Mahe B; Gastinne T; Blin N; Chevallier P; Guillaume T; Delaunay J; Ayari S; Saulquin B; Moreau A; Moreau P; Harousseau JL; Milpied N; Mohty M
Leuk Lymphoma; 2010 Aug; 51(8):1502-8. PubMed ID: 20583964
[TBL] [Abstract][Full Text] [Related]
19. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
